Mereo BioPharma (MREO) Return on Sales (2023 - 2025)
Historic Return on Sales for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to 129.92%.
- Mereo BioPharma's Return on Sales fell 846000.0% to 129.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 129.92%, marking a year-over-year decrease of 846000.0%. This contributed to the annual value of 2.95% for FY2023, which is N/A changed from last year.
- Per Mereo BioPharma's latest filing, its Return on Sales stood at 129.92% for Q3 2025, which was down 846000.0% from 29.23% recorded in Q2 2025.
- In the past 5 years, Mereo BioPharma's Return on Sales registered a high of 71.59% during Q1 2025, and its lowest value of 129.92% during Q3 2025.
- Moreover, its 3-year median value for Return on Sales was 9.11% (2023), whereas its average is 20.43%.
- Over the last 5 years, Mereo BioPharma's Return on Sales had its largest YoY gain of 742300bps in 2025, and its largest YoY loss of -846000bps in 2025.
- Mereo BioPharma's Return on Sales (Quarter) stood at 9.11% in 2023, then plummeted by -397bps to 45.32% in 2024, then plummeted by -187bps to 129.92% in 2025.
- Its Return on Sales stands at 129.92% for Q3 2025, versus 29.23% for Q2 2025 and 71.59% for Q1 2025.